As part of my practice in the past, I worked as an assessment rater on studies of several Alzheimer’s and dementia medications. I was involved in the earlier Solanezumab study and the more recent one. After the original study of individuals with Alzheimer’s disease showed no significant effect, they tried again in 2016 examining people with prodromal Alzheimer’s. This means people with the disease, but who have not yet developed dementia. We had a lot of hope for it.
Unfortunately, the second study found no significant impact either.
Solanezumab worked by removing plaque that is associated with Alzheimer’s disease. This seems to be the wrong goal though, as plaque may simply be a byproduct of Alzheimer’s, rather than the cause of it. Plaque may be what is left as neurons die.
Check out the study to learn more…
https://finance.yahoo.com/news/drugs-fail-slow-decline-inherited-123258835.html